In patients with chronic renal failure, mechanical and hemodynamic changes could occur in the lungs without obvious pulmonary symptoms and findings and their effects could pave the way to pulmonary functional disorders. In this study, pulmonary functional disorders and especially alveolocapillary defects, which are frequently seen in uremia, were determined in renal transplanted patients. Pulmonary functions and diffusion capacity were assessed in uremic patients (n = 20) and in successfully transplanted patients (n = 20) without any lung disease or pulmonary edema symptoms and findings. Patients were selected randomly among outpatients who were followed up in a Nephrology and Transplantation Unit. Forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and peak expiratory flow (PEF25–75) were measured. Single breath carbon monoxide diffusion test and diffusion lung capacity adjusted for hemoglobin concentration (DLAdj) were done. The means of the spirometric values such as FVC, FEV1 and FEV1/FVC were normal in the nondialyzed uremic group, but the PEF25–75 value (68.7%) and diffusion capacity (DLAdj 72.7%) were found to be slightly low. There were 2 patients with normal values and 18 patients with some functional abnormalities in this nondialyzed uremic group. The means of all spirometric parameters and diffusion capacities were found to be normal in the transplanted group. There were 7 patients with normal function and 13 patients with some functional abnormalities in this transplanted group. When the nondialyzed uremic group and the transplanted group were compared statistically, significant differences were found between their spirometric values (except for FVC) and their diffusion capacities. Even though the uremic patients did not show any symptoms, their pulmonary function tests, especially diffusion capacity, were found to be disturbed. Although the transplanted patients as a group had normal mean spirometric values and diffusion capacity there were nevertheless many individual transplanted patients with defective diffusion capacity and abnormal spirometric values.

Gibson DG: Haemodynamic factors in development of acute pulmonary edema in renal failure. Lancet 1966;ii:1217.
Crosbie WA, Snowden S, Parsons V: Changes in lung capillary permeability in renal failure. BMJ 1972;iv:388.
Rackow EC, Fern EI, Suprung C, Grodman RS: Uremic pulmonary edema. Am J Med 1978;64:1084–1088.
Morris PE, Bernard GR: Pulmonary complications of uremia; in Massry SG, Glassock J (eds): Textbook of Nephrology, ed 3. Baltimore, Williams & Wilkins, 1995, pp 1364–1367.
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Standardization of lung function tests, European Community for Steel and Coal. Officials Statement of European Respiratory Society. Eur Respir J 1993;6(suppl 16):5–40.
Cotes JE, Dabbs JM, Elwood PC, Hall AM, McDonald A, Saunders MJ: Iron-deficiency anaemia: Its effects on transfer factor for the lung (diffusing capacity) and ventilation and cardiac frequency during submaximal exercise. Clin Sci 1972;42:325–335.
De Pass SW, Stein J, Poppel MH, Jacobson HG: Pulmonary congestion and edema in uremia. JAMA 1956;162:5.
Bush A, Gabriel R: Pulmonary function in chronic renal failure: Effects of dialysis and transplantation. Thorax 1991;46:424–428.
Helkin RI, Maxwell MH, Murray JF: Uremic pneumonitis: A clinical, physiological study. Ann Intern Med 1962;57:1001.
Wallin CJB, Jacobson SH, Leksell LG: Subclinical pulmonary oedema and intermittent haemodialysis. Nephrol Dial Transplant 1996;11:2269–2275.
Ochs RH, Fishman AP: Depositional diseases of the lungs; in Fishman’s Pulmonary Diseases and Disorders, ed 3. New York, McGraw-Hill, 1998, pp 1151–1161.
Wolf A, Kummer F, Dorda W, Stummvoll HK, Pinggera WF: Renal failure and carbon monoxide diffusing capacity of the lung. Wien Klin Wochenschr 1979;91:189–193.
Üçok K, Gökbel H, Yeksan M, Bediz CS, Eser C, Turk S, Ergene N: The effects of rHuEPO administration on pulmonary functions in haemodialysis patients. Int J Artif Organs 1996;19:336–338.
Herrero JA, Alvarez-Sala JL, Coronel F, Moratilla C, Gamez C, Fernandez JM, Illescas ML, Barrientos A: Pulmonary function in chronic renal failure patients (abstract). European Dialysis and Transplant Association, 35th Congress of ERA 1998.
Moinard J, Guenard H: Membrane diffusion of the lungs in patients with chronic renal failure. Eur Respir J 1993;6:225–230.
Clausen JL: The diagnosis of emphysema, chronic bronchitis and asthma. Clin Chest Med 1990;11:405–416.
Carmichael DJS, Hamilton DV, Evans DB, Stovin PGI, Calne RY: Interstitial pneumonitis secondary to azathioprine in a renal transplant patient. Thorax 1983;38:951–952.
Tonue LT: Pulmonary toxicity associated with chemotherapeutic agents; in Fishman’s Pulmonary Diseases and Disorders, ed 3. New York, McGraw-Hill, 1998, pp 1003–1016.
Matthay RA, Twohigh K: Pulmonary effects of cytotoxic agents other than bleomycin. Clin Chest Med 1990;11:31–54.
Bedrossian CMW, Sussman J, Conklin RH, Kahan B: Azathioprine-associated interstitial pneumonitis. Am J Clin Pathol 1984;82:148–154.
Shihab-Eldeen A, Owun Wanne A, Junaid TA, Yacoub T: Experimental studies on multiorgan toxicity of cyclosporine-A in rats using a radiopharmaceutical and comparison with histopathological findings (abstract). Hum Exp Toxicol 1996;15:867–871.
Morales P, Cremades MJ, Pallardo L, Pastor A, Macian V: Effect of cyclosporin on lung diffusing capacity in renal transplant patients (abstract). Transplant Int 1995;8:481–484.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.